Abbott Raises 2026 Profit Forecast on Surging Medical Device Demand

Key Facts

In a move reflecting the healthcare sector's resilience against economic headwinds, Abbott Laboratories has raised its full-year 2026 profit guidance. This positive update follows a strong second-quarter performance, where the company witnessed significant momentum in its medical device and nutrition segments. The upgrade is fueled by four primary growth drivers: diabetes care, heart devices, diagnostics, and nutrition, setting the stage for a stronger performance in the second half of the year.

The guidance raise comes amid intensifying competition in the medical technology space, with peer Medtronic recently reporting a 4.8% increase in quarterly revenue according to recent earnings filings. Compared to previous quarters, Abbott continues to solidify its position in the continuous glucose monitoring (CGM) market, a segment experts estimate is growing at 15% annually per market research data. This trend highlights a sustained recovery in hospital procedures that bolster heart device sales.

Regarding market performance, ABT stock stood at $98.83 (close July 16, 2026), having traded between a day low of $94.99 and a high of $101.87 per market data. Investors are now monitoring broader macroeconomic indicators affecting consumer sentiment, as U.S. CPI data released on July 14 showed annual inflation slowing to 3.5%, which could support discretionary spending within the private healthcare sector.